IL-2 Without Antiretroviral Therapy, Trial Near Washington D.C.

The National Institute of Allergy and Infectious Diseases is recruiting persons with a CD4 count over 350 who do not plan to start antiretroviral therapy in the next year, for a phase II trial to determine the safety and efficacy of subcutaneous IL-2 without antiretrovirals for persons with relatively early HIV infection. They must have no antiretrovirals for six weeks before entering the trial, and "willingness to remain off antiretroviral therapy for 12 months or until a protocol-defined recommendation or required change is determined."

The only trial site is at the National Institutes of Health campus, in Bethesda, Maryland near Washington D.C.

For more information call Doreen Chaitt, R.N., M.P.H., 800-772-5464 ext. 428, or 301-402-0980 ext. 428.